Investors Face August 10 Deadline in ADMA Biologics Fraud Lawsuit

The lawsuit contends that ADMA Biologics failed to disclose critical information during the specified class period, specifically regarding related-party transactions and the use of channel stuffing to artificially boost revenue reports. Plaintiffs allege these practices left the company with inadequate internal controls, rendering its public statements regarding business operations materially false or misleading. As these details surfaced, the firm claims investors incurred significant financial losses.

Those interested in joining the action may do so without upfront out-of-pocket costs, as the firm operates on a contingency fee basis. While no class has been certified yet, investors retain the right to select their own counsel or remain absent class members. Serving as a lead plaintiff is not a requirement to participate in potential future recoveries, but it does allow an investor to play a more active role in directing the litigation. Interested parties should contact Phillip Kim at The Rosen Law Firm to review their eligibility and discuss the filing requirements before the court-mandated deadline.